Ticker Details
Denali Therapeutics Inc. Denali Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing therapeutics for neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis.
IPO Date:	December 8, 2017
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$3.14B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.77 | 2.74%
Avg Daily Range (30 D):	$0.49 | 2.46%
Avg Daily Range (90 D):	$0.53 | 2.68%

Institutional Daily Volume
Avg Daily Volume:	.64M
Avg Daily Volume (30 D):	1.3M
Avg Daily Volume (90 D):	1.41M

Trade Size
Avg Trade Size (Sh.):	69
Avg Trade Size (Sh.) (30 D):	59
Avg Trade Size (Sh.) (90 D):	63

Institutional Trades
Total Institutional Trades:	3,629
Avg Institutional Trade:	$2.74M
Avg Institutional Trade (30 D):	$2.53M
Avg Institutional Trade (90 D):	$2.54M
Avg Institutional Trade Volume:	.11M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$3.85M
Avg Closing Trade (30 D):	$4.69M
Avg Closing Trade (90 D):	$4.88M
Avg Closing Volume:	147.7K

News

May 14, 2026 @ 5:00 PM Oligonucleotides Clinical Trial Drug Development P... Source: Delveinsight

May 5, 2026 @ 8:33 PM Privium Fund Opens $5.07 Million Denali Stake Ahea... Source: Sara Appino

Apr 6, 2026 @ 5:26 PM Takeda Exits Dementia Drug Partnership With Denali... Source: Vandana Singh

Apr 1, 2026 @ 12:49 AM The $578 Billion Regenerative Medicine Market Has ... Source: Usa News Group

Feb 5, 2026 @ 7:00 PM Denali Therapeutics Presents Enzyme TransportVehic... Source: Denali Therapeutics Inc.

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$-2.88	$-.69	$-.73
Diluted EPS	$-2.88	$-.69	$-.73
Revenue	$M	$M	$M
Gross Profit
Net Income / Loss	$-508.02M	$-128.45M	$-128.55M
Operating Income / Loss	$-547.12M	$-137.36M	$-137.37M
Cost of Revenue
Net Cash Flow	$330.68M	$182.3M	$114.36M
PE Ratio